Cargando…

Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes

BACKGROUND: Nasopharyngeal carcinoma (NPC) shows a high proportion of lymph node metastasis, and treatment guidelines have been developed for positive nodes. However, no irradiation guidelines have been proposed for patients with enlarged neck lymph nodes (ENLNs) that do not meet the radiological cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Hao, Chen, Lei, Guo, Rui, Zhang, Yuan, Li, Wen-Fei, Mao, Yan-Ping, Sun, Ying, Zhang, Fan, Liu, Li-Zhi, Tian, Li, Ma, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364609/
https://www.ncbi.nlm.nih.gov/pubmed/28340596
http://dx.doi.org/10.1186/s40880-017-0199-2
_version_ 1782517356859228160
author Peng, Hao
Chen, Lei
Guo, Rui
Zhang, Yuan
Li, Wen-Fei
Mao, Yan-Ping
Sun, Ying
Zhang, Fan
Liu, Li-Zhi
Tian, Li
Ma, Jun
author_facet Peng, Hao
Chen, Lei
Guo, Rui
Zhang, Yuan
Li, Wen-Fei
Mao, Yan-Ping
Sun, Ying
Zhang, Fan
Liu, Li-Zhi
Tian, Li
Ma, Jun
author_sort Peng, Hao
collection PubMed
description BACKGROUND: Nasopharyngeal carcinoma (NPC) shows a high proportion of lymph node metastasis, and treatment guidelines have been developed for positive nodes. However, no irradiation guidelines have been proposed for patients with enlarged neck lymph nodes (ENLNs) that do not meet the radiological criteria of 10 mm in diameter for positive lymph nodes. This study aimed to determine the prognostic value and radiation dose for ENLNs in N0-category NPC patients treated with intensity-modulated radiotherapy (IMRT). METHODS: We reviewed the medical data of 251 patients with non-metastatic, N0-category NPC treated with IMRT. Receiver operating characteristic curves were used to calculate the cut-off value of the ENLN diameter for the prediction of disease failure. The biological equivalent dose (BED) for ENLNs was calculated. Patient survival was compared between the small and large ENLN groups. Independent prognostic factors were identified using the Cox proportional hazards model. RESULTS: The estimated 4-year regional relapse-free survival rate was higher in patients with ENLNs ≥5.5 mm than in those with ENLNs <5.5 mm (100% vs. 98.8%, P = 0.049), whereas disease-free, overall, and distant metastasis-free survival rates were similar between the two groups. After adjusting for various factors, ENLN diameter was not identified as an independent prognostic factor (P > 0.05 for all survival rates). In the subgroup analysis, patients receiving BED ≥72 Gy had a similar prognosis as patients receiving BED <72 Gy in both the small and large ENLN groups. The multivariate analysis also confirmed that BED ≥72 Gy was not associated with significantly improved prognosis in patients with N0-category NPC. CONCLUSIONS: A BED of 72 Gy to ENLNs is considerably sufficient to provide a clinical benefit to patients with N0-category NPC. Prospective studies are warranted to validate the findings in the present study.
format Online
Article
Text
id pubmed-5364609
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53646092017-03-28 Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes Peng, Hao Chen, Lei Guo, Rui Zhang, Yuan Li, Wen-Fei Mao, Yan-Ping Sun, Ying Zhang, Fan Liu, Li-Zhi Tian, Li Ma, Jun Chin J Cancer Original Article BACKGROUND: Nasopharyngeal carcinoma (NPC) shows a high proportion of lymph node metastasis, and treatment guidelines have been developed for positive nodes. However, no irradiation guidelines have been proposed for patients with enlarged neck lymph nodes (ENLNs) that do not meet the radiological criteria of 10 mm in diameter for positive lymph nodes. This study aimed to determine the prognostic value and radiation dose for ENLNs in N0-category NPC patients treated with intensity-modulated radiotherapy (IMRT). METHODS: We reviewed the medical data of 251 patients with non-metastatic, N0-category NPC treated with IMRT. Receiver operating characteristic curves were used to calculate the cut-off value of the ENLN diameter for the prediction of disease failure. The biological equivalent dose (BED) for ENLNs was calculated. Patient survival was compared between the small and large ENLN groups. Independent prognostic factors were identified using the Cox proportional hazards model. RESULTS: The estimated 4-year regional relapse-free survival rate was higher in patients with ENLNs ≥5.5 mm than in those with ENLNs <5.5 mm (100% vs. 98.8%, P = 0.049), whereas disease-free, overall, and distant metastasis-free survival rates were similar between the two groups. After adjusting for various factors, ENLN diameter was not identified as an independent prognostic factor (P > 0.05 for all survival rates). In the subgroup analysis, patients receiving BED ≥72 Gy had a similar prognosis as patients receiving BED <72 Gy in both the small and large ENLN groups. The multivariate analysis also confirmed that BED ≥72 Gy was not associated with significantly improved prognosis in patients with N0-category NPC. CONCLUSIONS: A BED of 72 Gy to ENLNs is considerably sufficient to provide a clinical benefit to patients with N0-category NPC. Prospective studies are warranted to validate the findings in the present study. BioMed Central 2017-03-24 /pmc/articles/PMC5364609/ /pubmed/28340596 http://dx.doi.org/10.1186/s40880-017-0199-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Peng, Hao
Chen, Lei
Guo, Rui
Zhang, Yuan
Li, Wen-Fei
Mao, Yan-Ping
Sun, Ying
Zhang, Fan
Liu, Li-Zhi
Tian, Li
Ma, Jun
Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
title Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
title_full Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
title_fullStr Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
title_full_unstemmed Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
title_short Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
title_sort clinical treatment considerations in the intensity-modulated radiotherapy era for patients with n0-category nasopharyngeal carcinoma and enlarged neck lymph nodes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364609/
https://www.ncbi.nlm.nih.gov/pubmed/28340596
http://dx.doi.org/10.1186/s40880-017-0199-2
work_keys_str_mv AT penghao clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT chenlei clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT guorui clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT zhangyuan clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT liwenfei clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT maoyanping clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT sunying clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT zhangfan clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT liulizhi clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT tianli clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes
AT majun clinicaltreatmentconsiderationsintheintensitymodulatedradiotherapyeraforpatientswithn0categorynasopharyngealcarcinomaandenlargednecklymphnodes